Updated May 2026 · Senate LDA filings
How Much Does Johnson & Johnson Spend on Lobbying?
Johnson & Johnson has disclosed $26.9M in federal lobbying across 7 policy areas, making it a top-tier spender in the LobbySpend index. Top reported issues include Health Issues, Pharmacy, Medical/Disease Research. The organization carries a LobbySpend Influence Score of 58/100 (grade C), based on disclosed spend, issue breadth, and revolving-door staffing.
Johnson & Johnson Lobbying Snapshot
| Total Disclosed Lobbying Spend | $26.9M |
| Most Recent Year (2024) | $5.8M |
| Influence Score | 58/100 (grade C) |
| Policy Issue Areas | 7 |
| Named Lobbyists | 18 |
| Revolving-Door Lobbyists | 3 |
| Industry | Pharmaceutical & Health Products |
| Filer Type | client |
| Rank Among Tracked Filers | #38 of 500 (top 8%) |
What the Disclosed Lobbying Covers
Johnson & Johnson's disclosed federal lobbying spend of $26.9M places it among the top-tier spenders tracked here — organizations that put real, recurring dollars behind their federal advocacy. Spending at this level usually involves a dedicated in-house team, multiple outside firms, and steady quarterly filings rather than one-off campaigns tied to a single bill.
Johnson & Johnson's disclosed lobbying covers 7 general issue areas — a moderate footprint. Filers in this range tend to engage on a coherent cluster of related topics rather than spreading effort across the federal agenda.
The Senate Lobbying Disclosure Act requires anyone who contacts covered federal officials on behalf of a paying client — and crosses time and dollar thresholds — to register and file quarterly. Filings are publicly available through the Senate Office of Public Records, which is the original source for every dollar figure on this page. The same filings feed downstream research at OpenSecrets, where you can cross-reference individual lobbyists, bills tracked, and related campaign contributions.
Top Issues Reported by Johnson & Johnson
- Health Issues
- Pharmacy
- Medical/Disease Research
- Copyright/Patent/Trademark
- Taxation
- Trade
- Government Issues
Top Spend Categories & Lobbyist Bench
3 of 18 lobbyists reported by Johnson & Johnson (17%) disclose prior federal government service — a small minority of the named bench.
Among the named bench, lobbyists with disclosed prior federal service include Christopher J. White (Former Senior Advisor, Office of the Vice President); Mark L. Kadesh (Former Professional Staff Member, Senate Armed Services Committee); Timothy C. Grady (Former Professional Staff Member, Senate Appropriations Committee). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.
Industry & Issue Context
Within the Pharmaceutical & Health Products sector, Johnson & Johnson ranks #0 of 33 tracked organizations by disclosed lobbying spend. The sector leader is Pharmaceutical Research & Manufacturers of America at $135.8M; the sector average is $16.4M. Johnson & Johnson's $26.9M sits 64% above the sector average.
Johnson & Johnson's LobbySpend Influence Score of 58/100 (grade C) is the most common grade in the index — it covers organizations with established but moderate federal advocacy programs. The score combines disclosed total spend (40%), issue breadth (30%), and revolving-door connections (30%). A C-grade is typical of mid-size corporations and trade associations with steady quarterly filings on a focused issue set.
Year-over-Year Trend
Across the 5-year window from 2020 to 2024, Johnson & Johnson's annual disclosed lobbying spend has climbed modestly — from $5.4M in 2020 to $5.8M in 2024, a change of +7%. Step-changes of this size often coincide with major bills moving through Congress, regulatory rulemakings affecting the organization's industry, or a leadership change in the relevant committee.
Annual Disclosed Spend, 2020–2024
| Year | Spend | YoY Change |
|---|---|---|
| 2020 | $5.4M | — |
| 2021 | $5.4M | +1.1% |
| 2022 | $5.1M | -5.9% |
| 2023 | $5.2M | +1.4% |
| 2024 | $5.8M | +11.0% |
How This Page Is Built (Methodology)
Every dollar on this page comes from quarterly filings submitted under the Lobbying Disclosure Act and published by the Senate Office of Public Records. We pull those filings via the lda.senate.gov public API, deduplicate amendments, and aggregate by registrant or client across the years shown. The "amount" for each filing is the larger of reported income (for lobbying firms) or reported expenses (for in-house programs), which is the standard convention used by both the Senate's own dashboards and outside researchers including OpenSecrets.
The LobbySpend Influence Score is a composite indicator: 40% disclosed total spend, 30% number of distinct general issue areas lobbied on, and 30% share of named lobbyists with prior federal government service. The score is descriptive — it summarizes what was disclosed — and should not be read as a measure of effectiveness, ethics, or political outcomes. Read the full methodology for the exact formulas, caveats, and known limitations of LDA disclosures.
Johnson & Johnson has disclosed $26.9M in federal lobbying across 7 policy areas, making it a top-tier spender in the LobbySpend index. Top reported issues include Health Issues, Pharmacy, Medical/Disease Research. The organization carries a LobbySpend Influence Score of 58/100 (grade C), based on disclosed spend, issue breadth, and revolving-door staffing.
This answer pulls from the Senate Lobbying Disclosure Office LD-2 filings, the authoritative federal source for U.S. federal lobbying disclosure. The headline number above is the direct answer; what follows is the additional context most readers need to use the answer for a real decision rather than just a fact lookup.
A practical caveat: the headline answer above reflects the most recent the Senate Lobbying Disclosure Office LD-2 filings vintage; underlying data is often revised for months after first publication, and the right reference for any specific decision is whichever vintage is current at the time of the decision. The as-of date is stamped on every page.